Precise MRD™

Molecular Residual Disease Monitoring

Up to 1,000
patient-specific variants per personalized panel[1]

1.45 ppm
limit of detection (LOD95)[1]

99.66%
clinical specificity across solid tumor types[1]

Up to 48%
of post-surgical MRD detections occur at ultrasensitive levels[2]

A personalized molecular picture of your patient's cancer care — at every step of their journey.

The Precise MRD™ Molecular Residual Disease Test is an ultrasensitive MRD assay built on whole-genome sequencing (WGS), giving you a deeper, more personalized understanding of your patient's clinical picture at every stage of care.

- **Detects circulating tumor DNA at ultrasensitive levels,** maintaining reliable detection even in low-shedding tumor types where disease is harder to find[1]
- **Adds molecular insights to the clinical picture** with results validated against known disease status and outcomes across prospective studies[1,2]
- **Offers exceptional specificity** for results you can use with confidence, minimizing the risk of false positives that create unnecessary clinical anxiety[1]
- **Reports quantitative results,** enabling you to track disease dynamics longitudinally

Designed to monitor disease across the cancer care continuum

Neoadjuvant
Identify non-responders, often early in their treatment course, who are at the highest risk of residual disease after surgery.[3]

Surveillance
Regular testing provides added assurance in disease clearance and early signals of recurrence that may warrant closer clinical attention.[2,5]

Post-surgical and adjuvant
Identify patients with microscopic levels of tumor remaining after surgery or curative intent therapy who are at the highest risk of disease recurrence.[2,4]

Metastatic
Dynamic monitoring of treatment response for metastatic disease, providing real-time insights into therapeutic effectiveness.[6]

Myriad Oncology™

Validated performance. Molecular insights. Built for real-world practice.

Precise MRD fits the way you already practice without adding to your workload.
Whether you're ordering for the first time or integrating it into routine care, Myriad supports you at every step.

Designed for the cancer care continuum:
Precise MRD enables cDNA testing across multiple tumor types and stages, supporting neoadjuvant monitoring and post-surgical MRD assessment to surveillance and recurrence detection.

Timely results for clinical decisions:
Precise MRD delivers initial results in approximately 3–4 weeks, with rapid follow-up testing in 7–10 days to enable ongoing disease monitoring.

Minimal tissue requirements:
Precise MRD accepts core needle biopsies alongside FFPE tissue, and requires only 4 x 5µm slides plus 1 H&E section; follow-up tests only require a standard blood draw.

Streamlined experience:
Straightforward ordering process and dedicated support for ordering, sample procurement, and results interpretation, designed to fit oncology workflows.

The Myriad Oncology portfolio continues to shape cancer care by delivering clinically actionable insights, supported by dedicated patient and clinician services.

Proven legacy of advancing precision medicine through cutting-edge molecular diagnostics

Fast turnaround to support timely clinical decisions

Streamlined ordering and reporting, including digital ordering platforms

Ongoing clinical education and support

LEARN MORE
myriad.com/oncology/precise-mrd-test

Each step. Every patient. Exactly what you need.

References: 1. Acevedo A, Colbert K, Trettin K, et al. Analytical validation of an ultrasensitive tumor-informed MRD assay. Presented at: American Association for Cancer Research Annual Meeting; April 17–22, 2026; San Diego, CA. Abstract 2598. **2.** Hashimoto T, Kobayashi S, Oki E, et al. Prognostic Impact of MRD Positivity at Ultra-sensitive ctDNA Levels Using a WGS-based Personalized Assay: A Pan-Cancer Analysis from MONSTAR-SCREEN-3. Presented at ASCO Annual Meeting; May 29 - June 2, 2026; Chicago IL. **3.** Foldi J, Hogan G, Johansen Taber C, et al. Early findings from MONITOR-Breast: ctDNA dynamics during neoadjuvant therapy using an ultrasensitive MRD assay. Presented at: American Association for Cancer Research Annual Meeting; April 17–22, 2026; San Diego, CA. **4.** Kagawa Y, Tsukada Y, Kotaka M, et al. Molecular residual disease detection using whole-genome sequencing-based ctDNA assay for resectable colorectal cancer in the MONSTAR-SCREEN-3 project. Presented at: ASCO Gastrointestinal Cancers Symposium; January 8–10, 2026; San Francisco, CA. Abstract G25. **5.** Upadhyay R, Alexander A, Ye Q, et al. Ultrasensitive ctDNA-based MRD monitoring predicts relapse in postoperative HR+ IBC. Presented at: San Antonio Breast Cancer Symposium; December 9–12, 2025; San Antonio, TX. Abstract 1012. **6.** An JA, Jasper J, Cabel L, et al. Ultrasensitive ctDNA monitoring during CDK4/6 inhibitor therapy for metastatic breast cancer. Presented at: ASCO Annual Meeting; May 30–June 3, 2025; Chicago, IL. Abstract 1073.

Myriad Oncology™